Treats T. vaginalis infection in females and males. ANDA 79065, held by Alembic. Metronidazole.
As of Nov 21, 2026, ANDA 79065 (Metronidazole), held by Alembic, was first approved by FDA on Jun 23, 2009, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Symptomatic Trichomoniasis. Metronidazole capsules USP 375 mg are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole capsules USP 375 mg are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 23, 2009 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metronidazole375MG · capsule;oral | Metronidazole | Rx |
| Feb 14, 2025 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jan 11, 2024 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jan 11, 2024 | Supplement 17Labeling · Standard review | Approved | None posted |
| Nov 4, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 4, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Sep 11, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 23, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters